Clinical Trials on Alzheiner's Disease

Total 379291 results

Washington University School of Medicine
Eli Lilly and Company; Hoffmann-La Roche; Avid Radiopharmaceuticals; National Institute... and other collaborators

Recruiting

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001 (DIAN-TU)

Dementia | Alzheimers Disease | Alzheimers Disease, Familial

United States, Canada, Italy, Argentina, Australia, Colombia, France, Ireland, Mexico, Netherlands, Puerto Rico, Spain, United Kingdom, Brazil, Japan, Germany
Washington University School of Medicine
Hoffmann-La Roche; National Institute on Aging (NIA); Alzheimer's Association

Terminated

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)

Dementia | Alzheimers Disease | Alzheimers Disease, Familial

United States, France, Spain, Ireland, Canada, Australia, Puerto Rico, United Kingdom
Washington University School of Medicine
Eli Lilly and Company; Hoffmann-La Roche; Avid Radiopharmaceuticals; National Institute... and other collaborators

Completed

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. (DIAN-TU)

Dementia | Alzheimers Disease | Alzheimers Disease, Familial

United States, Canada, France, Spain, Ireland, Australia, Puerto Rico, United Kingdom
Washington University School of Medicine
National Institute on Aging (NIA); Alzheimer's Association; Eisai Inc.; Accelerating...

Recruiting

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU) (DIAN-TU)

Dementia | Alzheimers Disease | Alzheimers Disease, Familial

United States, Canada, Italy, Argentina, Australia, Colombia, Netherlands, Puerto Rico, Spain, United Kingdom, France, Ireland, Mexico, Brazil, Japan, Germany
Washington University School of Medicine
Hoffmann-La Roche; Genentech, Inc.; National Institute on Aging (NIA); Alzheimer...

Suspended

A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation (DIAN-TU)

Dementia | Alzheimers Disease | Alzheimers Disease, Familial

United States, Canada, Italy, France, Spain, Ireland, Argentina, Australia, Colombia, Germany, Mexico, Netherlands, Puerto Rico, United Kingdom
Biogen

Terminated

An Observational Study of Aducanumab-avwa in Participants With Alzheimer's Disease in the US

Alzheimers Disease

United States
Hoffmann-La Roche

Recruiting

Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease

Alzheimers Disease

Korea, Republic of, United States, Canada, Poland, Spain, Australia, Japan, Chile, United Kingdom
Hoffmann-La Roche

Terminated

A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD) (SKYLINE)

Alzheimers Disease

United States, United Kingdom, Korea, Republic of, Poland, Canada, Australia, Argentina, Spain, Sweden, Italy
Oslo University Hospital
Sykehuset Innlandet HF; Sykehuset i Vestfold HF

Unknown

Cognitive Behavioural Therapy for Persons With MCI or Mild Dementia

Alzheimers' Disease

Norway
Hoffmann-La Roche

Completed

A Single Ascending Dose Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Intravenously Administered RO7126209 in Healthy Participants

Alzheimers Disease

United States
Avid Radiopharmaceuticals

Completed

The Feasibility of Florbetapir Quantitation

Alzheimers Disease

United States
Avid Radiopharmaceuticals

Terminated

A Phase 0, Open Label, Multi-Center, Exploratory and Safety Study of [F-18]T808 (T808)

Alzheimers Disease

United States
University of Aarhus

Completed

Identifying Potential Effects of Liraglutide on Degenerative Changes

Alzheimers Disease

Denmark
Elizabeth K Rhodus
National Institute on Aging (NIA)

Recruiting

Person-Environment Fit for Persons With Dementia

Alzheimer Disease | Dementia Alzheimers

United States
Bijan Najafi, PhD
BioSensics

Recruiting

Care Coordination System for People With Dementia

Dementia | Alzheimer Disease | Dementia Alzheimers

United States
Avid Radiopharmaceuticals

Terminated

A Phase 0, Open Label, Multi-center Exploratory and Safety Study of [F-18]T807

Alzheimers Disease | AD

United States
Baycrest

Completed

Low Dose Ionizing Radiation Using CT Scans as a Potential Therapy for Alzheimer's Dementia: A Pilot Study (LDIR-CT-AD)

Dementia Alzheimers

Canada
Alzinova AB
CRST Oy

Recruiting

A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease

Alzheimer Disease | Dementia Alzheimers | Dementia, Mild

Finland
Oslo University Hospital
South Eastern Area Health Service

Unknown

Multiple Nutritional Deficiencies Causing Dementia of the Alzheimer Type (ALZ-vit)

Mild Cognitive Impairment | Alzheimers Disease

Norway
Molecular NeuroImaging
Institute for Neurodegenerative Disorders

Completed

Evaluation of [123I] AV83 and SPECT in Patients With Alzheimer Disease in Comparison to Healthy Controls

Alzheimers Disease

United States
Novartis Pharmaceuticals
Amgen; Banner Alzheimer's Institute

Terminated

A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (GS2)

Alzheimers Disease

Spain, United States, Belgium, Italy, Germany, Australia, Israel, Taiwan, Japan, Canada, Korea, Republic of, United Kingdom, France, China, Argentina, Finland, Singapore, Portugal, Chile, Mexico, Switzerland, Netherlands, Iceland, Puerto... and more
Novartis Pharmaceuticals
National Institute on Aging (NIA); Amgen; Banner Alzheimer's Institute

Terminated

A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (GS1)

Alzheimers Disease

United States, Belgium, United Kingdom, Germany, Australia, Canada, Spain, Finland, Switzerland, Netherlands
Molecular NeuroImaging
Institute for Neurodegenerative Disorders

Completed

Use of [123I] AV39 and SPECT Imaging as a Marker of Protein Disposition in Subjects With Alzheimer Disease Compared to Healthy Subjects

Alzheimers Disease

United States
Novo Nordisk A/S

Active, not recruiting

A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease

Alzheimers Disease

United States, Canada, Italy, Sweden, Denmark, Switzerland
Institute for Neurodegenerative Disorders
Molecular NeuroImaging

Completed

Evaluation of [123I] MNI-187 and SPECT in Patients With Alzheimers Disease in Comparison to Healthy Subjects

Alzheimers Disease

United States
University of North Carolina, Chapel Hill
National Institute on Aging (NIA)

Completed

Telephone-delivered Mindfulness Intervention for African American Dementia Caregivers

Alzheimer Dementia | Dementia Alzheimers | Caregiver

United States
University Hospital, Clermont-Ferrand

Not yet recruiting

Interest of the Reborn® Doll as a TO in the Care of Residents With Alzheimer's Disease or a Related Disorder (PROTMA)

Dementia Alzheimers

France
Barcelonabeta Brain Research Center, Pasqual Maragall...

Completed

Experimental Study of the Impact of a Group Therapy Psychological Intervention for Caregivers of Alzheimer's Disease Patients (EMOCUIDA)

Psychological Support to Caregivers of Azlheimer's Patients

Spain
Massachusetts General Hospital
National Institutes of Health (NIH); National Institute on Aging (NIA)

Active, not recruiting

MASC: Reducing Stress for Caregivers (MASC)

Dementia Alzheimers | Alzheimer Disease and Related Dementias

United States
Ascentys Ltd

Not yet recruiting

Feasibility Study of Game Technology in the Early Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease (G:DATA)

Dementia Alzheimers

United Kingdom
University Hospital, Basel, Switzerland

Recruiting

Validation of a Novel Self-Administered Cognitive Assessment Tool (CogCheck) in Patients With Mild and Major Neurocognitive Disorder Predominantly Due to Alzheimer's Disease (CogCheck-MC)

Neurocognitive Disorders | Cognition Disorders | Mild Cognitive Impairment | Dementia Alzheimers

Switzerland
University of North Carolina, Chapel Hill
National Institute on Aging (NIA)

Enrolling by invitation

The Nightlight Falls Prevention Study

Alzheimer Disease | Aging | Fall Injury | Dementia Alzheimers | Dementia of Alzheimer Type

United States
William Beaumont Hospitals

Completed

Establishment of a Bank of Biospecimens for Future Research on Age-related Cognitive Disorders

Dementia | Alzheimers Disease

United States
Vivoryon Therapeutics N.V.
Amsterdam UMC, location VUmc; Nordic Bioscience A/S

Completed

A Study to Evaluate Safety and Tolerability of Different Doses and Efficacy of PQ912 in Subjects With MCI and Mild AD (VIVIAD)

Early Alzheimers Disease | Mild Cognitive Impairment Due to AD

Netherlands, Spain, Denmark, Germany, Poland
Novoic Limited

Recruiting

Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - FUTURE Extension (FUTURE-US)

Alzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's Disease

United States
Novoic Limited

Recruiting

Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech - PAST Extension (AMYPRED-PAST)

Alzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's Disease

United Kingdom
Novoic Limited

Completed

Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping (AMYPRED-US)

Alzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's Disease

United States
University of Southern California
Alzheimer's Therapeutic Research Institute; American Heart Association; Schaeffer...

Recruiting

Financial Incentives and Recruitment to the APT Webstudy (FIND-AD)

Dementia | Alzheimer Disease | Prodromal Alzheimer's Disease | Preclinical Alzheimer's Disease

United States
University of Southern California
National Institute on Aging (NIA); Alzheimer's Therapeutic Research Institute; Brigham and Women's Hospital and other collaborators

Active, not recruiting

TRC-PAD Program: In-Clinic Trial-Ready Cohort (TRC-PAD)

Dementia | Alzheimer Disease | Prodromal Alzheimer's Disease | Preclinical Alzheimer's Disease

United States
Novoic Limited

Completed

Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech (AMYPRED)

Alzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's Disease

United Kingdom
Novoic Limited

Recruiting

Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech - FUTURE Extension (AMYPRED-FUTURE)

Alzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's Disease

United Kingdom
Mclean Hospital
National Institute on Aging (NIA)

Not yet recruiting

Passive Sensor Identification of Digital Biomarkers to Assess Effects of Orally Administered Nicotinamide Riboside (Emerald-NRAD)

Neurocognitive Disorders | Neurodegenerative Diseases | Cognitive Impairment | Cognitive Dysfunction | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Mental Disorder | Neurocognitive Dysfunction | Dementia Alzheimers
University of Southern California
National Institute on Aging (NIA); Alzheimer's Therapeutic Research Institute; Alzheimer's Clinical Trials Consortium (ACTC)

Enrolling by invitation

Alzheimer's Plasma Extension (APEX)

Preclinical Alzheimer's Disease | Early Preclinical Alzheimer's Disease

United States
Novoic Limited

Recruiting

Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - PAST Extension (PAST-US)

Alzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's Disease | Normal Cognition

United States
University Hospital, Bordeaux
Ministry for Health and Solidarity, France

Completed

MEMENTO-VAScular COmponents of Dementia (VASCOD)

Alzheimer's Disease (AD) | Alzheimer's Disease (AD) Related Disorders

France
Zealand University Hospital
Rigshospitalet, Denmark

Unknown

Non-expensive and Widely Available Tests as Diagnostic Tools in Dementia and Their Ability to Predict Disease Progression (DEMPROG)

Mild Cognitive Impairment | Alzheimers Disease

Denmark
University of Colorado, Denver
National Institute on Aging (NIA)

Completed

VIdeo Telehealth in ALzheimer's: NeuroPsychology (VITAL-NP) (VITAL-NP)

Suspected Typical Alzheimer's Disease (AD) | Suspected Atypical Alzheimer's Disease (AD)

United States
Cognito Therapeutics, Inc.

Enrolling by invitation

Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)

Cognitive Impairment | Alzheimer Disease | Mild Cognitive Impairment | Dementia Alzheimers | Dementia of Alzheimer Type | AD | Dementia, Mild | Dementia Moderate

United States
University of Wisconsin, Madison
National Institute on Aging (NIA); Arizona State University

Not yet recruiting

Speech Pattern Evaluation and Analysis for Knowledge of AD (SPEAK-AD)

Wisconsin Alzheimer's Disease Research Center | Wisconsin Registry for Alzheimer's Prevention

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo

Nervous System Diseases | Mental Disorder | Alzheimer's Type | Agitation Associated With Alzheimer's Disease

United States, Germany, France, Bulgaria, Spain, Slovenia, Croatia, Serbia, Russian Federation, Ukraine, Canada, United Kingdom

Clinical Trials on Alzheiner's Disease

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ukraine

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations